OCTA in Mild Cognitive Impairment and Alzheimer's Disease
Study Details
Study Description
Brief Summary
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD) or other neurodegenerative disease, multiple sclerosis, and Huntington's disease.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Using a multidisciplinary approach, this study aims to yield new insight into the vascular pathophysiology of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) Parkinson's Disease (PD) or other neurodegenerative disease. The investigators propose to develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature in persons with MCI and AD, PD or other neurodegenerative disease multiple sclerosis, and Huntington's disease..
The investigators hypothesize that microvascular network alterations in the retina mirror and possibly precede changes in the cerebral microcirculation seen in these diseases. Using advanced image analysis, the investigators aim to evaluate markers of reduced capillary blood flow and non-perfusion in the superficial and deep retinal vascular plexuses and choriocapillaris imaged using OCTA, in a resolution not previously possible, that would complement already established retinal structural markers and increase their sensitivity and specificity in the early detection of MCI and AD, PD, multiple sclerosis, and Huntington's disease. or other neurodegenerative disease.
This study looks to provide a proof of concept for OCTA-based retinal microvascular biomarkers as an effective screening tool in cognitive aging.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Case 500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease |
Device: Retinal Imaging
Non-invasive OCTA scan of retina
|
Active Comparator: Controls Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease. |
Device: Retinal Imaging
Non-invasive OCTA scan of retina
|
Outcome Measures
Primary Outcome Measures
- Foveal avascular zone [12 months]
Differences in Foveal avascular zone size
- Vessel Density [12 months]
Differences in Superficial and Deep Capillary Plexus Vessel Density
- Choroidal Thickness [12 months]
Differences in subfoveal choroidal thickness between the two groups
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with neurodegenerative disease (MCI/ADPD/MS/HD)
-
Age-gender-race-matched controls.
Exclusion Criteria:
-
History of known or suspected diagnosis of non-AD
-
Associated dementia
-
Diabetes mellitus
-
Inability to cooperate with or complete testing
-
Evidence of glaucoma
-
Macular degeneration
-
Other neurologic or age-related ocular conditions that would impact OCTA segmentation. -Eyes that have had intraocular surgery, other than cataract surgery, will be excluded
-
If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Duke University Medical Center | Durham | North Carolina | United States | 27705 |
Sponsors and Collaborators
- Duke University
- University of Edinburgh
Investigators
- Principal Investigator: Dilraj Grewal, MD, Duke University
- Study Director: Sharon Fekrat, MD, Duke University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00082598